Q-Linea — Share Issue/Capital Change 2025

Mar 31, 2025

Q-LINEA

New number of shares and votes in Q-linea AB (publ)

The number of shares and votes in Q-linea AB (publ) (the "Company") has increased during March as a result of due to the allocation of the remaining units in the rights issue of units, which was resolved by the board of directors on November 5, 2024, with subsequent approval by the extraordinary general meeting on December 6, 2024, and the directed issue of units to guarantors in the aforementioned rights issue, resolved by the board on February 10, 2025, with authorization, has now been executed. This increase is due to the notification from Landegren Gene Technology AB to the Inspectorate of Strategic Products (ISP) being left without action, enabling the allocation of the remaining 221,543,930 units in the issues.

As of March 31, 2025, the total number of shares in the Company amounts to 4,448,288,096 shares (previously 4,005,200,236 shares), with one vote each. All shares are common shares. The share capital amounts to SEK 222,414,404.80 (previously SEK 200,260,011.80). As of March 31, 2025, Q-linea AB holds 328,472 of its own shares.

For more information, please contact:

Stuart Gander, President & CEO, Q-linea
Stuart.Gander@qlinea.com
+1 857 409 7463

Christer Samuelsson, CFO /IR, Q-linea AB
Christer.Samuelsson@qlinea.com
+46 (0) 70-600 15 20

About Q-linea

Q-linea's rapid AST system, ASTar®, accelerates and simplifies the time-sensitive workflows faced during the treatment of patients with bloodstream infections and sepsis. Hospitals use ASTar to vastly reduce the time to optimal antimicrobial therapies and ensure that patients receive the correct treatments sooner—when time matters most. We are helping to create sustainable healthcare, now and in the future, and safeguard the effectiveness of antibiotics for generations to come.

Q-linea is headquartered in Uppsala, Sweden and has regional offices in Italy and the USA, with partnerships worldwide.

ASTar Instrument and ASTar BC G- Consumable kit are CE-IVD marked and FDA 510(k) cleared. For more information, please visit www.qlinea.com

This information is information that Q-linea is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication at 2025-03-31 10:50 CEST.

Attachments

New number of shares and votes in Q-linea AB (publ)

Q-linea • Dag Hammarskjölds väg 52A • SE-752 37 Uppsala